Способ получения 6-(1-оксиэтил) ангидропенициллина в виде 5,6-транс-изомера

Изобретение касается производных гетероциклических соединений, в частности способа получения 5,6- транс-изомера-6-(1-оксиэтил)ангид- ропенициллина (АП) - полупродукта синтеза пенемовых и карбонемовых антибиотиков. Цель изобретения - создание нового полупродукта, позволяющего вести стереоспецифический синтез антибиотиков. Синтез АП ведут реакцией 6,6-дибромангидропеницилли- на и метилмагнийхлорида в среде инертного органического растворителя при (-45)-(-15) с. Образующийся продукт обрабатывают ацетальдегидом в этих же условиях и получают 6-монобром- замещенный ангидропенициллин в виде дис-изомера. Этот продукт восстанавливают в инертном растворителе с помощью Zn/Ag, а затем выделяют целевой продукт в виде 5,6-транс-изоме- ра. Выход 42-56,6%, т.пл. 173-174 с, брутто-формула . «о СО ...

“Antibiotic of carbapénem with alkyl group substituted in position 4 and their salts nontoxic and pharmaceutically acceptable”.

2-PENEM ANTIBIOTICS

Retinoid-like compounds

Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors

Antibacterial penem compounds

Penem compounds of the formula I are described. The definitions of the substituents X, Y and Z can be taken from Patent Claim 1. They can be obtained by cyclisation of compounds of the formula II in which R<''> is an ester protective group, followed by removal of this protective group in cases where Z denotes hydrogen. The compounds have a good activity as antibacterial agents. ...

Antibacterial penem compounds

A description is given of the novel compounds of the formula I and of their pharmaceutically usable salts. The meanings of the substituents A, Alk, Alk', R20, Y and Z are as defined in Claim 1. These are active antibacterial agents and can also be used as starting substances for the preparation of other such agents. They are obtained by cyclising compounds of the formula II in which Y, Q, R'' and T have the meaning given in Claim 5. ...

2-PENEM ANTIBIOTICS

Conformationally restricted biphenyl derivatives for use as hepatitis C virus inhibitors

Sulfated alpha-glycolipid derivatives a cell adhesion inhibitors

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors

Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors

CHEMICAL INTERMEDIATES

PROCEDE STEREOCONTROLE DE PREPARATION D'ACETOXYAZETIDINONE

PROCEDE DE CONTROLE STEREOSPECIFIQUE DE TRANSFORMATION DE L'ACIDE 6-AMINOPENICILLANIQUE EN UNE AZETIDINONE OPTIQUEMENT ACTIVE DE FORMULE : (CF DESSIN DANS BOPI) DANS LAQUELLE ;R REPRESENTE UN GROUPE PROTECTEUR HYDROXY, PAR UTILISATION D'UNE 6,6-DIHALOANHYDROPENICILLINE OU D'UNE 6,6-BIS (PHENYLSELENYL) ANHYDROPENICILLINE INTERMEDIAIRE.

Heterocyclic derivatives as hepatitis C virus inhibitors

CONFORMATIONALLY RESTRICTED BIPHENYL DERIVATIVES FOR USE AS HEPATITIS C VIRUS INHIBITORS

Lighting device

2-SUBSTITUTED AND 2,6-DISUBSTITUTED PENEM ANTIBIOTICS

Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors

HEPATITIS C VIRUS INHIBITORS

2-SUBSTITUTED AND 2,6-DISUBSTITUTED PENEM ANTIBIOTICS

CARBAPENEM DERIVATIVES

Selective retinoic acid analogs

4-substituted alkyl carbapenem antibiotics

PENICILLIN INTERMEDIATES

Hepatitis c virus inhibitors

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

ANTIBIOTIC C-3 DITHIOACETAL-SUBSTITUTED CARBAPENEM COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF

PENICILLIN INTERMEDIATES

Sulfated-glycolipid derivatives as cell adhesion inhibitors

ANTIBIOTIC C-3 DITHIOACETAL-SUBSTITUTED CARBAPENEM COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF

CHEMICAL INTERMEDIATES

Sulphated beta-glycolipid derivatives as cell adhesion inhibitors

4-substituted alkyl carbapenem antibiotics

INTERMEDIATES FOR 2-PENEMS

4-substituted alkyl carbapenem antibiotics

THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

CARBAPENEM DERIVATIVES

Hepatitis C virus inhibitors

INTERMEDIATES FOR 2-PENEMS

Hepatitis C virus inhibitors

Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

ANTIBIOTIC C-3 DITHIOACETAL-SUBSTITUTED CARBAPENEM COMPOUND, ITS COMPOSITION AND USE

PURPOSE: To provide a new compd. having antimicrobial activity which is useful for the treatment for microbial infection. CONSTITUTION: This compd. is expressed by formula I (wherein, R1 is H, 1-6C alkyl; (n) is 0 to 2; R3 is H, 1-6C alkyl; R2 is 1-6C alkyl, cyano, -CONH2, -CH2OH, -CH2NH2, etc), for example, (4R,5S,6S)-6-[1'(R)-hydroxyethyl]-4- methyl-3-[[[(5-methyl-1,3,4-oxadiazol-2-yl)thio]methyl]thio]-7-oxo-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid. The compd. expressed by formula I is obtd. by allowing a compd. expressed by formula II (wherein M+ is a metal cation or H) to react with an alkylating agent expressed by formula III (wherein Q is a deprotective group such as iodine) in the presence of an amine base such as trialkylamine to obtain a compd., then eliminating a protecting group of the obtd. compd. by hydrolysis with an enzyme, and then oxidizing sulfur to form a sulfinyl or sulfonyl group. COPYRIGHT: (C)1992,JPO ...

HEPATITIS C VIRUS INHIBITORS

LIGHTING DEVICE

Hepatitis c virus inhibitors

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that, at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.

4-SUBSTITUTED ALKYL CARBAPENEM ANTIBIOTICS

Heterocyclic derivatives as hepatitis c virus inhibitors

The present disclosure relates to compounds of formula (I), their compositions and their use in the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.

UN COMPUESTO DE FORMULA (I) DONDE R1 , R1 , R2 , R2 , R3, R3, R',4 R4, U Y U' SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO DE REIVINDICACIONES; COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE; Y SU USO PARA TRATAR LA INFECCIÓN DEL VIRUS DE LA HEPATITIS C.

Process for preparing 4-substituted alkyl carbapenem antibiotics

HEPATITIS C VIRUS INHIBITORS

IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS

Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.

COMPUESTO DE FÓRMULA DONDE, R1 , R2, R3, R4, R1' , R2' ,R3 ', R4', SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO DE REIVINDICACIONES, COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE; Y SU USO PARA TRATAR LA INFECCIÓN DEL VIRUS DE LA HEPATITIS C.
...

Sulfated-glycolipid derivatives as cell adhesion inhibitors

Hepatitis C virus inhibitors

The present disclosure relates to compounds of structure (I), compositions and Methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors

The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. 2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein m is 0.3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , whereinu and v are each independently 0 or 1; and{'sup': 1', '2, 'each Rand Ris independently selected from alkyl and halo.'}4. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein u and v are each 0.5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 ,{'sub': '2', 'sup': '16', 'wherein X is selected from CHand CHR.'}6. A compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 ,{'sub': '2', 'wherein X is CH.'}7. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 3', '4, 'wherein Rand Rare each independently selected from hydrogen, haloalkyl, and trialkylsilylalkoxyalkyl.'}8. A compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 ,{'sup': 3', '4, 'wherein Rand Rare each independently selected from hydrogen and haloalkyl.'}9. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , whereinn is 0, 1, or 2; and{'sup': '16', 'when present, each Ris halo.'}10. A compound of claim 9 , or a pharmaceutically acceptable salt thereof claim 9 , wherein n is 0.11. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 5', '6, 'wherein Rand Rare independently selected from hydrogen and alkyl.'}12. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 11', '12, 'wherein Rand Rare independently selected from hydrogen and alkyl.'}13. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , ...

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. 4. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.5. The composition of further comprising one or two additional compounds having anti-HCV activity.6. The composition of wherein at least one of the additional compounds is an interferon or a ribavirin.7. The composition of wherein the interferon is selected from interferon alpha 2B claim 6 , pegylated interferon alpha claim 6 , consensus interferon claim 6 , interferon alpha 2A claim 6 , and lymphoblastiod interferon tau.8. The composition of wherein at least one of the additional compounds is selected from interleukin 2 claim 5 , interleukin 6 claim 5 , interleukin 12 claim 5 , a compound that enhances the development of a type 1 helper T cell response claim 5 , interfering RNA claim 5 , anti-sense RNA claim 5 , Imiqimod claim 5 , ribavirin claim 5 , an inosine 5′-monophospate dehydrogenase inhibitor claim 5 , amantadine claim 5 , and rimantadine.9. The composition of wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease claim 5 , HCV serine protease claim 5 , HCV polymerase claim 5 , HCV helicase claim 5 , HCV NS4B protein claim 5 , HCV entry claim 5 , HCV assembly claim 5 , HCV egress claim 5 , HCV NS5A protein claim 5 , and IMPDH for the treatment of an HCV infection.10. A composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , and a pharmaceutically acceptable carrier.11. The composition of further comprising one or two additional compounds having anti-HCV activity.12. The composition of wherein at least one of the ...

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. 2. A compound of wherein m and n are each 1.3. A compound of wherein at least one of X and Y is S.4. A compound of wherein X and Y are each S.5. A compound of whereinq and s are each 0; andu and v are each 0.6. A compound of wherein at least one of Rand Ris hydrogen.7. A compound of wherein Rand Rare —C(O)—R.8. A compound of wherein each Ris independently selected from arylalkyl and heterocyclyl.9. A compound of wherein X is selected from CHR claim 2 , and C(R); and Y is selected from CH claim 2 , CHR claim 2 , and C(R).10. A compound of wherein each Rand Ris independently selected from halo and hydroxy.11. A compound of wherein each Rand Ris independently selected from hydrogen claim 10 , Calkyl claim 10 , and halo.12. A compound of wherein Rand Rare hydrogen.13. A compound of wherein at least one of Rand Ris hydrogen.14. A compound of wherein Rand R—C(O)—R.15. A compound of wherein each Ris independently selected from alkoxy and arylalkyl.16. A compound of wherein X and Y are each CH.17. A compound of wherein at least one of q and s is 0.18. A compound of wherein q and s are each 0.19. A compound of wherein Rand Rare independently selected from hydrogen claim 18 , alkyl claim 18 , halo claim 18 , and haloalkyl.20. A compound of wherein at least one of Rand Ris hydrogen.21. A compound of wherein Rand Rare —C(O)—R.22. A compound of wherein each Ris independently selected from alkoxy claim 21 , alkoxyalkyl claim 21 , alkyl claim 21 , alkylcarbonylalkyl claim 21 , aryl claim 21 , arylalkenyl claim 21 , arylalkoxy claim 21 , arylalkyl claim 21 , aryloxyalkyl claim 21 , cycloalkyl claim 21 , (cycloalkyl)alkyl claim 21 , cycloalkyloxyalkyl claim 21 , heterocyclyl claim 21 , heterocyclylalkyl claim 21 , ...

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. 2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein m is 0.3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , whereinu and v are each independently 0 or 1; and{'sup': 1', '2, 'each Rand Ris independently selected from alkyl and halo.'}4. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein u and v are each 0.5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein X is selected from CHand CHR.6. A compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , wherein X is CH.7. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rare each independently selected from hydrogen claim 1 , haloalkyl claim 1 , and trialkylsilylalkoxyalkyl.8. A compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein Rand Rare each independently selected from hydrogen and haloalkyl.9. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , whereinn is 0, 1, or 2; and{'sup': '16', 'when present, each Ris halo.'}10. A compound of claim 9 , or a pharmaceutically acceptable salt thereof claim 9 , wherein n is 0.11. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rare independently selected from hydrogen and alkyl.12. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rare independently selected from hydrogen and alkyl.13. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 7', '14, 'wherein at least one of Rand Ris hydrogen.'}14. A compound of claim 1 , or a ...

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. 2. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.3. The composition of further comprising one or two additional compounds having anti-HCV activity.4. The composition of wherein at least one of the additional compounds is an interferon or a ribavirin.5. The composition of wherein the interferon is selected from interferon alpha 2B claim 4 , pegylated interferon alpha claim 4 , consensus interferon claim 4 , interferon alpha 2A claim 4 , and lymphoblastiod interferon tau.6. The composition of wherein at least one of the additional compounds is selected from interleukin 2 claim 3 , interleukin 6 claim 3 , interleukin 12 claim 3 , a compound that enhances the development of a type 1 helper T cell response claim 3 , interfering RNA claim 3 , anti-sense RNA claim 3 , Imiqimod claim 3 , ribavirin claim 3 , an inosine 5′-monophosphate dehydrogenase inhibitor claim 3 , amantadine claim 3 , and rimantadine.7. The composition of wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease claim 3 , HCV serine protease claim 3 , HCV polymerase claim 3 , HCV helicase claim 3 , HCV NS4B protein claim 3 , HCV entry claim 3 , HCV assembly claim 3 , HCV egress claim 3 , HCV NSSA protein claim 3 , and IMPDH for the treatment of an HCV infection.8. A method of treating an HCV infection in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.9. The method of further comprising administering one or two additional compounds having anti-HCV ...

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. 1. A compound selected from:(1R,1′R)-2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(2-oxo-1-phenylethanol);(2S,2′S)-1,1′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(1-oxo-2-phenyl-2-propanol);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-benzoyl-2-pyrrolidinyl)-1H-imidazole);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-(phenylacetyl)-2-pyrrolidinyl)-1H-imidazole);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-((2R)-2-methoxy-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazole);(2R,2′R)-1,1′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(1-oxo-3-phenyl-2-propanol);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-propionyl-2-pyrrolidinyl)-1H-imidazole);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-(cyclopropylcarbonyl)-2-pyrrolidinyl)-1H-imidazole);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-(cyclopropylacetyl)-2-pyrrolidinyl)-1H-imidazole);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-((2R)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinyl)-1H-imidazole);2,2′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxoethanamine);(2R,2′R)-1,1′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(1-oxo-2-propanol);(2R,2′R)-1,1′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(3-methyl-1-oxo-2-butanol);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-((2R)-2-phenyl-2-(1-pyrrolidinyl)acetyl)-2-pyrrolidinyl)-1H-imidazole);4,4′-(4,4′-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))dimorpholine;5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-(((3S)-3-fluoro-1-pyrrolidinyl)(phenyl)acetyl)-2-pyrrolidinyl)-1H-imidazole);5,5′-(4,4′-biphenyldiyl)bis(2-((2S)-1-(((3S)-3-fluoro-1-pyrrolidinyl)( ...

AUGMENTED REALITY METHOD AND APPARATUS FOR ASSISTING AN OPERATOR TO PERFORM A TASK ON A MOVING OBJECT

Augmented reality-based method, apparatus and system for assisting an operator to perform a task on a moving object according to at least one characteristic of the object, uses projection of light onto the object according to object tracking task instruction data as it moves through the working zone to provide a visual instruction for the operator about the task to perform on the object. 1. An augmented reality method for assisting an operator to perform a task within a working zone on an object moving along a path intersecting the working zone and according to at least one characteristic of said object , said method being for use with a sensor unit configured to generate data indicative of said object characteristic at a detecting position upstream said working zone , said method comprising the steps of:i) generating task instruction data according to said characteristic indicative data;ii) estimating successive positions of said object as it moves toward and through the working zone to generate object position tracking data;iii) processing said task instruction data and said object position tracking data to generate object tracking task instruction data; andiv) projecting light according to said object tracking task instruction data onto said object as it moves through the working zone to provide a visual instruction for the operator about the task to perform on the object.2. The method according to claim 1 , wherein said task instruction data are indicative of one of a plurality of object sorting instructions for the operator.3. The method according to claim 1 , wherein said object is moving along a substantially linear path under action of a transport means in a transport direction and wherein said sensor unit is further configured to generate data indicative of a transverse position coordinate of said object relative to the transport direction claim 1 , said estimating step ii) includes:a) measuring displacement of said transport means to derive successive ...

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R 0 , R 2 , R 4 , R a , R b , X 1 , X 2 , X 3 and X 4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R, R, R, R, X, Xand s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments. 4. The compound as defined in wherein Ris Y—Z— which is selected from the group consisting of:{'sub': 6', '10, 'sup': 'a5', 'C-Caryl substituted with 0 to 2 Rgroups;'}{'sub': 6', '10', '1', '4, 'sup': a5', 'a1, 'C-C-aryl-C-C-alkyl, wherein the aryl portion of which is independently substituted with 0 to 3 Rgroups, and the alkyl portion of which is independently substituted with 0 to 2 Rgroups;'}{'sub': 6', '10', '1', '3, 'sup': a5', 'a1, 'C-C-aryl-C-C-alkyloxy, wherein the aryl portion of which is independently substituted with 0 to 3 Rgroups, and the alkyl portion of which is independently substituted with 0 to 2 Rgroups;'}{'sub': 6', '10', '1', '3, 'sup': a5', 'a1, 'C-C-aryl-C-C-alkylthio, wherein the aryl portion of which is independently substituted with 0 to 3 Rgroups, and the alkyl portion of which is independently substituted with 0 to 2 Rgroups;'}{'sub': 6', '10, 'sup': 'a5', 'C-Caryloxy substituted with 0 to 2 Rgroups;'}{'sub': 6', '10, 'sup': 'a5', 'C-Carylthio substituted with 0 to 3 Rgroups;'}{'sub': 6', '10', '2', '6, 'sup': a5', 'a1, 'C-C-aryl-C-C-alkynyl, wherein the aryl is substituted with 0 to 3 Rgroups and the alkynyl is substituted with 0 to 3 Rgroups;'}{'sup': 'a5', '4- to 10-membered ring heterocyclyl substituted with 0 to 3 Rgroups;'}{'sub': 1', '4, 'sup': a5', 'a1, '4- to 10-membered ring heterocyclyl-C-C-alkyl, wherein the heterocyclo portion of which is independently substituted with 0 to 3 Rgroups, and the alkyl portion of which is independently substituted with 0 to 2 Rgroups;'}{'sub': 1', '4, 'sup': a5', 'a1, '4- to 10-membered ring heterocyclyl-C-C-alkyloxy, wherein the ...

METHOD AND SYSTEM FOR REGULATING OIL FLOW TO AN ENGINE

Systems and methods for regulating oil flow to an engine are described herein. An oil pressure target for the engine is determined based on one or more engine operating parameters. Oil flow to the engine is controlled based on the oil pressure target. Closed-loop feedback of oil pressure of the engine is obtained from at least one sensor during the controlling of the oil flow to the engine. A pressure difference between the oil pressure target and the closed-loop feedback of the oil pressure of the engine is determined. The oil flow to the engine is adjusted based on the pressure difference. 1. A method for regulating oil flow to an engine , the method comprising:determining an oil pressure target for the engine based on one or more engine operating parameters;controlling oil flow to the engine based on the oil pressure target;obtaining closed-loop feedback of oil pressure of the engine from at least one sensor during the controlling of the oil flow to the engine;determining a pressure difference between the oil pressure target and the closed-loop feedback of the oil pressure of the engine; andadjusting the oil flow to the engine based on the pressure difference.2. The method of claim 1 , wherein determining the oil pressure target comprises determining the oil pressure target based on the one or more engine operating parameters and a mode of operation of the engine.3. The method of claim 2 , wherein the mode of operation corresponds to any one of: flight idle claim 2 , ground idle claim 2 , forward thrust and reverse thrust.4. The method of claim 1 , wherein determining the oil pressure target comprises obtaining the oil pressure target from an oil pressure map indicating oil pressure as a function of engine rotational speed.5. The method of claim 1 , wherein the one or more engine operating parameters comprise any one or more of: atmospheric pressure claim 1 , atmospheric temperature claim 1 , oil temperature claim 1 , engine rotational speed and engine filter ...

INTERNALLY COOLED SEAL RUNNER

A contact seal assembly for a shaft of a gas turbine engine includes a seal runner adapted to be connected to the shaft and rotatable relative to a carbon ring. The seal runner includes concentric inner and outer annular portions radially spaced apart to define at least one internal fluid passage between the inner and outer annular portions of the seal runner. 1. A contact seal assembly for a shaft of a gas turbine engine , comprising:one or more carbon ring segments mounted in a fixed position within a housing; andan annular seal runner adapted to be connected to the shaft of the gas turbine engine and rotatable relative to the carbon ring segments, the seal runner being disposed adjacent to and radially inwardly from the carbon ring segments and abutting thereagainst during rotation of the seal runner to form a contact interface between the seal runner and the carbon ring segments which forms a substantially fluid tight seal;the seal runner comprising concentric inner and outer annular portions which are radially spaced apart to define therebetween at least one internal fluid passage, said internal fluid passage formed by a plurality of serially interconnected passage segments which intersect each other to create single tortuous fluid flow path through the internal fluid passage, the plurality of serially interconnected passage segments and said single tortuous fluid flow path defined thereby being disposed at a single radial position between the inner and outer annular portions of the seal runner such that all of the plurality of serially interconnected passage segments are disposed at common diameter within the seal runner, the internal fluid passage being adapted to receive cooling oil therein for cooling the seal runner from within, and the seal runner having one or more oil scoops integrally formed in one of the inner and outer annular portions and disposed in fluid flow communication with the internal fluid passage, the one or more oil scoops feeding cooling ...

Internally cooled seal runner

A contact seal assembly for a shaft of a gas turbine engine includes a seal runner adapted to be connected to the shaft and rotatable relative to a carbon ring. The seal runner includes concentric inner and outer annular portions radially spaced apart to define at least one internal fluid passage between the inner and outer annular portions of the seal runner.

Heterocyclic compounds as inhibitors of platelet aggregation

The present invention provides compounds of Formula I: wherein Y, AA, W, R 3′ R 2 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 , X 4 and X 5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. This Continuation application claims the benefit of U.S. Ser. No. 14/934,538 filed Nov. 6, 2015, now allowed, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 14/488,990 filed Sep. 17, 2014, now U.S. Pat. No. 9,227,961, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 14/030,199 filed Sep. 18, 2013, now U.S. Pat. No. 8,900,566, which in turn is a Continuation application which claims the benefit of U.S. Ser. No. 13/650,374 filed Oct. 12, 2012, now U.S. Pat. No. 8,642,025, which in turn is a Continuation application which claims the benefit of Non-Provisional application U.S. Ser. No. 11/835,462 filed Aug. 8, 2007, now U.S. Pat. No. 8,329,159 which in turn claims the benefit of U.S. Provisional Application U.S. Ser. No. 60/836,996 filed Aug. 11, 2006, now expired, all of which are incorporated by reference in their entireties.The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.HCV is a major human pathogen, infecting an estimated 170 million persons worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma.Presently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, leading to sustained efficacy in 40% of patients. Recent clinical results demonstrate that pegylated alpha ...

METHOD FOR TESTING A SEAL OF A SEALED BEARING CAVITY

The method for testing the integrity of a seal of a cavity in an engine includes providing a sealed test tank external to the cavity, the test tank having an internal volume that is particularly selected, as described herein. A pressure differential is generated between the test tank and the cavity, by creating an initial test pressure within the test tank that is different than an ambient pressure inside the cavity. Gas flow between the test tank and the cavity is then permitted, and a change in pressure within the test tank is measured, as is a test time required for the pressure inside the test tank to reach a reference pressure. The measured test time is compared with a predetermined reference time, and the integrity of the seal may be confirmed when the test time is greater than or equal to the reference time. 1. A method for testing the sealing integrity of at least one seal of a cavity in an engine , the cavity and surroundings being at ambient pressure prior to testing , the method comprising:a) providing a sealed test tank external to the cavity and ensuring that the cavity is sealed with the exception of the at least one seal;b) generating a pressure differential between the test tank and the cavity by creating an initial test pressure within the test tank that is different than the ambient pressure;c) fluidly connecting the test tank and the cavity to initiate pressure balancing between the test tank and the cavity, thereby permitting ambient gas flow through the at least one seal either into or out of the cavity;d) measuring a change in pressure within the test tank and a test time required for the pressure inside the test tank to reach a reference pressure, the reference pressure being a preselected pressure between the initial test pressure and the ambient pressure; ande) comparing the test time with a predetermined reference time, wherein the at least one seal has a desired sealing integrity when the test time is greater than or equal to the reference ...

SYSTEM AND METHOD FOR PREPARING CRUSTACEAN BODY PARTS FOR MEAT EXTRACTION

A system and method for preparing a shelled crustacean body part for meat extraction are provided. The method involves capturing an image of said body part, evaluating the thickness of the shell from the image, determining from the thickness evaluation at least one laser parameter for forming a line of weakness within the shell, the line of weakness being dimensioned to facilitate meat extraction, while preserving the sensory characteristics of the meat, and sweeping a laser beam on the body part in accordance with the laser parameter to form the line of weakness within the shell. The method and system provide the advantage of facilitating meat extraction without compromising the quality or commercial value of the meat all while increasing productivity and performance in comparison with completely manual extraction techniques. 1. A method of preparing a shelled crustacean body part for meat extraction , said method comprising the steps of:capturing an image of said body part;evaluating the thickness of the shell from said image;determining from said thickness evaluation at least one laser parameter for forming a line of weakness within said shell, said line of weakness being dimensioned to facilitate meat extraction, while preserving the sensory characteristics of the meat; andsweeping a laser beam on said body part in accordance with said laser parameter to form said line of weakness within said shell in order to facilitate meat extraction.2. The method of claim 1 , wherein said image is a three-dimensional profile image of said body part.3. The method of claim 1 , wherein said line of weakness is a shell-deep cut.4. The method of claim 1 , wherein said laser parameter is selected from the group consisting of: the number of times said laser beam is to be swept; the speed at which said laser beam is to be swept; and the intensity of said laser beam.5. The method of claim 1 , further comprising the step of determining from said image a laser path along which said ...

Hepatitis c virus inhibitors

The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to compounds of structure (I), compositions and Methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Lighting device

The current invention is an intelligent lighting device capable of being connected to a network and being controlled by a host computer also connected to the network.

Hepatitis c virus inhibitors

The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

Hepatitis c virus inhibitors

Disclosed is a bis diazole imidazole substituted biphenyl compound of formula (I) where the substituents are as described in the description. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament for treating HCV infection. Examples of compounds of formula (I) are: methyl ((1S)-1-(((2S)-2-(5-( 4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyIbutanoyl)-2-pyrrolidinyI)-1H-imidazol-5-yl)-4-biphenyIyl)-1H -imidazol-2-yl)1-pyrrolidinyl)carbonyl)-2-methyIpropyI)carbamate; (1R,1'R)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl(2S)-2,1-prrrolidinediyI))bis(N,N-dimethyl-2-oxo-1-phenylethanamine) and methyl ((1S)-2-((2S)-2-(5-(4'-(2-((2S)-1-((2R)-2-( diethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-1-methyl-2-oxoethyl)carbamate.

hepatitis c virus inhibitor compounds and pharmaceutical composition comprising them

inibidores do vírus da hepatite c. a presente descrição refere-se aos compostos, composições e métodos para o tratamento de infecção pelo vírus da hepatite c (hcv). são também descritas composições farmacêuticas contendo tais compostos e métodos para utilizar estes compostos no tratamento de infecção por hcv. hepatitis c virus inhibitors. the present description relates to compounds, compositions and methods for treating hepatitis c virus (hcv) infection. pharmaceutical compositions containing such compounds and methods of using these compounds in the treatment of hcv infection are also described.

Hepatitis c virus inhibitors

Hepatitis C virus inhibitors

Un compuesto de fórmula (I)**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que m y n son independientemente 0, 1 o 2; q y s son independientemente 0, 1, 2, 3 o 4; u y v son independientemente 0, 1, 2 o 3; X se selecciona de O, S, S(O), SO2, CH2, CHR5 y C(R5)2; con la condición de que cuando n es 0, X se selecciona de CH2, CHR5 y C(R5)2; Y se selecciona de O, S, S(O), SO2, CH2, CHR6 y C(R6)2; con la condición de que cuando m es 0, Y se selecciona de CH2, CHR6 y C(R6)2; cada R1 y R2 se selecciona independientemente de alcoxi, alcoxialquilo, alcoxicarbonilo, alquilo, arilalcoxicarbonilo, carboxi, formilo, halo, haloalquilo, hidroxi, hidroxialquilo, -NRaRb, (NRaRb)alquilo y (NRaRb)carbonilo; R3 y R4 se seleccionan cada uno independientemente de hidrógeno y R9-C(O)-, y R9-C(S)-; cada R5 y R6 se selecciona independientemente de alcoxi, alquilo, arilo, halo, haloalquilo, hidroxi y -NRaRb, en dondel alquilo puede opcionalmente formar un anillo de tres hasta seis miembros fusionados con un átomo de carbono adyacente, en dondel anillo de tres hasta seis miembros está opcionalmente sustituido con uno o dos grupos alquilo. A compound of formula (I) ** Formula ** or a pharmaceutically acceptable salt thereof, in which m and n are independently 0, 1 or 2; q and s are independently 0, 1, 2, 3 or 4; u and v are independently 0, 1, 2 or 3; X is selected from O, S, S (O), SO2, CH2, CHR5 and C (R5) 2; with the proviso that when n is 0, X is selected from CH2, CHR5 and C (R5) 2; Y is selected from O, S, S (O), SO2, CH2, CHR6 and C (R6) 2; with the proviso that when m is 0, Y is selected from CH2, CHR6 and C (R6) 2; each R1 and R2 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxy, hydroxyalkyl, -NRaRb, (NRaRb) alkyl and (NRaRb) carbonyl; R3 and R4 are each independently selected from hydrogen and R9-C (O) -, and R9-C (S) -; each R5 and R6 is independently selected from alkoxy, alkyl ...

Hepatitis c virus inhibitors.

La presente descripción se refiere a compuestos, composiciones y métodos para el tratamiento de la infección del virus de la hepatitis C (HCV). También se describen las composiciones farmacéuticas que contienen tales compuestos y métodos para uso de estos compuestos en el tratamiento de la infección del HCV.

Hepatitis c virus inhibitors

The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

HEPATITIS C VIRUS INHIBITORS

Chemical compounds, and salts thereof, preparations comprising the same compound, combinations and such compounds for use in the treatment of disease

Hepatitis c virus inhibitors

Hepatitis c virus inhibitors (hcv)

Hepatitis c virus inhibitors

HEPATITIS C VIRUS INHIBODERS

1.- Un compuesto de la fórmula (I)o una sal farmacéuticamente aceptable del mismo, caracterizado porque m y n son independientemente 0, 1, ó 2; q y s son independientemente 0, 1, 2, 3, ó 4; u y v son independientemente 0, 1, 2, ó 3; X se selecciona de O, S, S(O), SO2, CH2, CHR5, y C(R5)2; con la condición de que cuando n es 0, X se selecciona de CH2, CHR5, y C(R5)2; Y se selecciona de O, S, S(O), SO2, CH2, CHR6, y C(R6)2; con la condición de que cuando m es 0, Y se selecciona de CH2, CHR6, y C(R6)2; cada R1 y R2 es independientemente seleccionado de alcoxi, alcoxialquilo, alcoxicarbonilo, alquilo, arilalcoxicarbonilo, carboxi, formilo, halo, haloalquilo, hidroxi, hidroxialquilo, -NRaRb, (NRaRb) alquilo, y (NRaRb) carbonilo; R3 y R4 son cada uno independientemente seleccionados de hidrógeno y R9-C(O)-, y R9-C(S)-;cada R5 y R6 es independientemente seleccionado de alcoxi, alquilo, arilo, halo, haloalquilo, hidroxi, y NRaRb, en donde el alquilo puede opcionalmente formar un anillo de tres hasta seis miembros fusionados con un átomo de carbono adyacente, en donde el anillo de tres hasta seis miembros es opcionalmente substituido con uno o dos grupos alquilo; R7 y R8 son cada uno independientemente seleccionados de hidrógeno, alcoxicarbonilo, alquilo, arilalcoxicarbonilo, carboxi, haloalquilo, (NRaRb)carbonilo, y trialquilsililalcoxialquilo; y cada R9 es independientemente seleccionado de alcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilalquilo, arilo, arilalquenilo, arilalcoxi, arilalquilo, ariloxialquilo, cicloalquilo, (cicloalquil)alquenilo, (cicloalquil)alquilo, cicloalquiloxialquilo haloalquilo, heterociclilo, heterociclilalquenilo, heterociclilalcoxi, heterociclilalquilo, heterocicliloxialquilo, hidroxialquilo, NRcRd, (NRcRd)alquenilo, (NRcRd)alquilo, y (NRcRd)carbonilo. 1. A compound of the formula (I) or a pharmaceutically acceptable salt thereof, characterized in that m and n are independently 0, 1, or 2; q and s are ...

SUSPENSION VIRUS INHIBITIONS C

Η παρούσα αποκάλυψη σχετίζεται με μια ένωση του Χημικού Τύπου (Ι), με συνθέσεις και μεθόδους για την αγωγή της λοίμωξης από τον ιό της ηπατίτιδας C (ΗCV). Επίσης αποκαλύπτονται και θεραπευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις και μέθοδοι για χρήση αυτών των ενώσεων στην αγωγή της λοίμωξης από τον HCV.

Hepatitis C virus inhibitors

Un compuesto que es ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2- pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; o una sal farmacéuticamente aceptable del mismo, para su uso en terapia. A compound that is ((1S) -1 - (((2S) -2- (5- (4 '- (2 - ((2S) -1 - ((2S) -2 - ((methoxycarbonyl) amino) - 3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2-methylpropyl) methyl carbamate; or a pharmaceutically acceptable salt thereof, for use in therapy.

Hepatitis C virus inhibitors

Hepatitis c virus inhibitors

HEPATITIS C VIRUS INHIBITORS

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE m Y n SON CADA UNO 0-2; q Y s SON CADA UNO 0-4; u Y v SON CADA UNO 0-3; X ES O, S, S(O), SO2, ENTRE OTROS, CON LA CONDICION QUE CUANDO n ES 0 X ES CH2, CHR5 O C(R5)2; Y ES O, S, CH2, ENTRE OTROS, CON LA CONDICION QUE CUANDO m ES 0 Y ES CH2, CHR6 O C(R6)2; R1 Y R2 SON CADA UNO ALCOXI, ALCOXIALQUILO, CARBOXI, HALO, ENTRE OTROS; R3 Y R4 SON CADA UNO H, R9-C(O)- O R9-C(S)-; R5 Y R6 SON CADA UNO ALCOXI, ALQUILO, ARILO, HALO, ENTRE OTROS; R7 Y R8 SON CADA UNO H, ALCOXICARBONILO, ALQUILO, ENTRE OTROS; R9 ES ALCOXI, ALQUILCARBONILO, ARILOXIALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (2S,2'S)-2,2'-(4,4'-BIFENILDIILBIS(1H-IMIDAZOL-5,2-DIIL))DI(1-PIRROLIDINCARBOXILATO) DE DI-TERT-BUTILO; (2S)-2-(4-(3'-(2S)-1-TERT-BUTOXICARBONIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-3-BIFENIL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINCARBOXILATO DE TERT-BUTILO; 5,5'-(4,4'-BIFENILDIIL)BIS(2-((2S)-2-PIRROLIDINIL)-1H-IMIDAZOL); ENTRE OTROS. TAMBIEN SE REFIERE A METODOS Y PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS INHIBEN EL FUNCIONAMIENTO DE LA PROTEINA NS5A CODIFICADA POR EL VIRUS DE LA HEPATITIS C REFERS TO A COMPOUND OF FORMULA I WHERE m AND n ARE EACH 0-2; q AND s ARE EACH 0-4; u AND v ARE EACH 0-3; X IS O, S, S (O), SO2, AMONG OTHERS, WITH THE CONDITION THAT WHEN n IS 0 X IS CH2, CHR5 OR C (R5) 2; Y IS O, S, CH2, AMONG OTHERS, WITH THE CONDITION THAT WHEN m IS 0 AND IS CH2, CHR6 OR C (R6) 2; R1 AND R2 ARE EACH ALCOXY, ALCOXYALKYL, CARBOXY, HALO, AMONG OTHERS; R3 AND R4 ARE EACH H, R9-C (O) - OR R9-C (S) -; R5 AND R6 ARE EACH ALCOXY, ALKYL, ARYL, HALO, AMONG OTHERS; R7 AND R8 ARE EACH H, ALCOXICARBONIL, ALKYL, AMONG OTHERS; R9 IS ALCOXY, ALKYLCARBONYL, ARYLOXYALKYL, ARYL, AMONG OTHERS. PREFERRED COMPOUNDS (2S, 2'S) -2,2 '- (4,4'-BIPHENYLDIYLBIS (1H-IMIDAZOL-5,2-DIYL)) DI (1-PYRROLIDINE CARBOXYLATE) DI-TERT-BUTYL; (2S) -2- (4- (3 '- (2S) -1-TERT-BUTOXICARBONIL) -2-PYRROLIDINYL) -1H-IMIDAZOL-5-IL) -3-BIPHENYL) ...

Hepatitis C virus inhibitors

Hepatitis c virus inhibitors

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors

The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

Una formulación farmacéutica adaptada para la administración oral que comprende ((1S)-1-(((2S)-2-(5-(4'-(2- ((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1- pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; o una sal farmacéuticamente aceptable del mismo. A pharmaceutical formulation adapted for oral administration comprising ((1S) -1 - (((2S) -2- (5- (4 '- (2- ((2S) -1 - ((2S) -2- ( (methoxycarbonyl) amino) -3-methylbutanoyl) -2-pyrrolidinyl) -1H-imidazol-5-yl) -4-biphenylyl) -1H-imidazol-2-yl) -1-pyrrolidinyl) carbonyl) -2-methylpropyl) methyl carbamate; or a pharmaceutically acceptable salt thereof.

Hepatitis C viral inhibitors

Compounds for preparing hepatitis c virus inhibitors

The present disclosure relates to the preparation of a compound for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pyrrolidinyl or biphenyl derivatives which are used in a process for preparing the HCV inhibiting compound.

Hepatitis c virus inhibitors

Hepatitis C virus inhibitors

The present disclosure relates to compounds of Formula (1), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and compounds of Formula (1) for use in a method of treating an HCV infection.

Hepatitis C virus inhibitors

Hepatitis c virus inhibitors

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

Hepatitis c virus inhibitors

Hepatitis c virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

Hepatitis c virus inhibitors

SUSPENSION VIRUS INHIBITIONS C

Η παρούσα αποκάλυψη σχετίζεται με μια ένωση του Χημικού Τύπου (I), με συνθέσεις και μεθόδους για την αγωγή της λοίμωξης από τον ιό της ηπατίτιδας C (HCV). Επίσης αποκαλύπτονται και θεραπευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις και μέθοδοι για χρήση αυτών των ενώσεων στην αγωγή της λοίμωξης από τον HCV. The present disclosure relates to a compound of Formula (I), with compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are therapeutic compositions containing such compounds and methods for the use of these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

SUSPENSION VIRUS INHIBITIONS C

Η παρούσα αποκάλυψη σχετίζεται με μια ένωση του Χημικού Τύπου (I), με συνθέσεις και μεθόδους για την αγωγή της λοίμωξης από τον ιό της ηπατίτιδας C (HCV). Επίσης αποκαλύπτονται και θεραπευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις και μέθοδοι για χρήση αυτών των ενώσεων στην αγωγή της λοίμωξης από τον HCV. The present disclosure relates to a compound of Formula (I), with compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are therapeutic compositions containing such compounds and methods for the use of these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also di sclosed are pharmaceutical compositions containing such compounds and method s for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

hepatitis c virus inhibitors

Hepatitis c virus inhibitors

Hepatitis C virus inhibitors

The present disclosure relates to compounds having the Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Compounds for preparing hepatitis c virus inhibitors

The present disclosure relates to the preparation of a compound for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pyrrolidinyl or biphenyl derivatives which are used in a process for preparing the HCV inhibiting compound.

Hepatitis C virus inhibitors

Foreliggende beskrivelse angår forbindelser, preparater og metoder for behandling av hepatitt C virus- (HCV) infeksjon. Også beskrevet er farmasøytiske preparater inneholdende slike forbindelser og metoder for anvendelse av disse forbindelser ved behandling av HCV-infeksjon.

Hepatitis C virus inhibitors

Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors

The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.

Hepatitis c virus inhibitors

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.

Hepatitis C virus inhibitors

Un compuesto de Fórmula (I)o una sal farmacéuticamente aceptable del mismo, en laqueA y B son cada uno fenilo;D y E son cada uno un anillo aromático de cinco miembros que contiene uno, dos, o tres heteroátomosseleccionados independientemente entre nitrógeno, oxígeno, y azufre; a condición de que al menos uno de losgrupos D y E sea distinto de imidazol;R1 y R2 están seleccionados independientemente entre hidrógeno, R310 -C(O)-; ycada R3 están seleccionados independientemente entre alcoxi, alcoxialquilo, alcoxicarbonilo,alcoxicarbonilalquilo, alquilo, alquilcarbonilalquilo, arilo, arilalquenilo, arilalcoxi, arilalquilo, ariloxialquilo,cicloalquilo, (cicloalquil)alquenilo, (cicloalquil)alquilo, cicloalquiloxialquilo, haloalquilo, heterociclilo,heterociclilalquenilo, heterociclilalcoxi, heterociclilalquilo, heterocicliloxialquilo, hidroxialquilo, -NRcRd,(NRcRd)alquenilo, (NRcRd)alquilo, y (NRcRd15 )carbonilo. A compound of Formula (I) or a pharmaceutically acceptable salt thereof, in which A and B are each phenyl; D and E are each a five-membered aromatic ring containing one, two, or three heteroatoms independently selected from nitrogen, oxygen , and sulfur; provided that at least one of groups D and E is different from imidazole; R1 and R2 are independently selected from hydrogen, R310 -C (O) -; Each R3 is independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonylalkyl, aryl, arylalkyl, arylalkoxy, arylalkyl, aryloxyalkyl, cycloalkyl, (cycloalkyl) alkenyl, (cycloalkyl) alkyl, cycloalkyl, heterocyclyl, heterocyclyl, alkylalkyl, cycloalkyl, heterocyclyl, alkylalkyl, alkyl heterocyclylalkyl, heterocyclyloxyalkyl, hydroxyalkyl, -NRcRd, (NRcRd) alkenyl, (NRcRd) alkyl, and (NRcRd15) carbonyl.

Hepatitis c virus inhibitors.

La presente invención se refiere a composiciones de (4,4'-diimidazolil)bifenilos y a métodos para el tratamiento del virus de la hepatitis C (VHC). También se describen composiciones farmacéuticas que contienen estos compuestos y métodos para el uso de estos compuestos en el tratamiento de infección por VHC.

Hepatitis c virus inhibitors

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.

Heterocyclic derivatives as hepatitis c virus inhibitors

Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors

The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

Hepatitis c virus inhibitors

The present disclosure relates to compounds of structure (I), compositions and Methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.